CO2023017619A2 - Composiciones líquidas de liberación prolongada de mexiletina para administración oral - Google Patents
Composiciones líquidas de liberación prolongada de mexiletina para administración oralInfo
- Publication number
- CO2023017619A2 CO2023017619A2 CONC2023/0017619A CO2023017619A CO2023017619A2 CO 2023017619 A2 CO2023017619 A2 CO 2023017619A2 CO 2023017619 A CO2023017619 A CO 2023017619A CO 2023017619 A2 CO2023017619 A2 CO 2023017619A2
- Authority
- CO
- Colombia
- Prior art keywords
- mexiletine
- extended
- oral administration
- liquid compositions
- controlled release
- Prior art date
Links
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 title abstract 4
- 229960003404 mexiletine Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000013265 extended release Methods 0.000 title 1
- 239000007788 liquid Substances 0.000 title 1
- 238000013270 controlled release Methods 0.000 abstract 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 abstract 2
- 239000003456 ion exchange resin Substances 0.000 abstract 2
- 229920003303 ion-exchange polymer Polymers 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- 206010061533 Myotonia Diseases 0.000 abstract 1
- 208000012905 Myotonic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202131026198 | 2021-06-11 | ||
| PCT/EP2022/065917 WO2022258842A1 (en) | 2021-06-11 | 2022-06-10 | Extended-release compositions of mexiletine for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023017619A2 true CO2023017619A2 (es) | 2024-03-27 |
Family
ID=82258238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0017619A CO2023017619A2 (es) | 2021-06-11 | 2023-12-15 | Composiciones líquidas de liberación prolongada de mexiletina para administración oral |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240173272A1 (https=) |
| EP (1) | EP4351549A1 (https=) |
| JP (1) | JP2024521460A (https=) |
| CN (1) | CN117858702A (https=) |
| AU (1) | AU2022288145A1 (https=) |
| BR (1) | BR112023025925A2 (https=) |
| CA (1) | CA3221594A1 (https=) |
| CL (1) | CL2023003702A1 (https=) |
| CO (1) | CO2023017619A2 (https=) |
| MX (1) | MX2023014773A (https=) |
| WO (1) | WO2022258842A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD146547A5 (de) | 1978-07-15 | 1981-02-18 | Boehringer Sohn Ingelheim | Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen |
| CN101466390B (zh) * | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| CN101032462A (zh) | 2006-12-20 | 2007-09-12 | 浙江大学 | 盐酸美西律缓释制剂及制备方法 |
| WO2010149760A2 (en) | 2009-06-24 | 2010-12-29 | Shire Llc | Mexiletine amino acid and peptide prodrugs and uses thereof |
| US20120196933A1 (en) | 2010-12-23 | 2012-08-02 | Richard Franklin | Mexiletine prodrugs |
-
2022
- 2022-06-10 WO PCT/EP2022/065917 patent/WO2022258842A1/en not_active Ceased
- 2022-06-10 CA CA3221594A patent/CA3221594A1/en active Pending
- 2022-06-10 BR BR112023025925A patent/BR112023025925A2/pt unknown
- 2022-06-10 MX MX2023014773A patent/MX2023014773A/es unknown
- 2022-06-10 JP JP2023576212A patent/JP2024521460A/ja active Pending
- 2022-06-10 EP EP22734249.0A patent/EP4351549A1/en active Pending
- 2022-06-10 AU AU2022288145A patent/AU2022288145A1/en active Pending
- 2022-06-10 CN CN202280056092.8A patent/CN117858702A/zh active Pending
-
2023
- 2023-12-10 US US18/534,710 patent/US20240173272A1/en active Pending
- 2023-12-11 CL CL2023003702A patent/CL2023003702A1/es unknown
- 2023-12-15 CO CONC2023/0017619A patent/CO2023017619A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022288145A1 (en) | 2024-01-04 |
| MX2023014773A (es) | 2024-01-15 |
| BR112023025925A2 (pt) | 2024-02-27 |
| CN117858702A (zh) | 2024-04-09 |
| CL2023003702A1 (es) | 2024-05-03 |
| EP4351549A1 (en) | 2024-04-17 |
| WO2022258842A1 (en) | 2022-12-15 |
| JP2024521460A (ja) | 2024-05-31 |
| CA3221594A1 (en) | 2022-12-15 |
| US20240173272A1 (en) | 2024-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015017307A (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington. | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| MX2018008021A (es) | Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones. | |
| JP2023541432A5 (https=) | ||
| JP2017506624A5 (https=) | ||
| JP2013541583A5 (https=) | ||
| JP2018507243A5 (https=) | ||
| JP2018513188A5 (https=) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| PE20221338A1 (es) | Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina | |
| EP4700016A3 (en) | Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| CL2016001707A1 (es) | Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11). | |
| RU2015115398A (ru) | N-ацетил-L-цистеин для применения в экстракорпоральном оплодотворении | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| CO2023017619A2 (es) | Composiciones líquidas de liberación prolongada de mexiletina para administración oral | |
| JP2019529569A5 (https=) | ||
| JP2019535830A5 (https=) | ||
| MX2018011293A (es) | Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| JP2015512439A5 (https=) | ||
| ZA202200330B (en) | Pharmaceutical composition of imatinib | |
| TW202615093A (zh) | 再使用於已中止免疫檢查點抑制劑給藥之癌症患者之免疫檢查點抑制劑的治療效果提高用醫藥 |